COMMUNIQUÉS West-GlobeNewswire

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
17/05/2024
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice LONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles [...]
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
17/05/2024
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17/05/2024
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Oculis updates share capital for its existing at-the-market offering program
17/05/2024
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal [...]
DBV Technologies Announces Plan to Implement ADS Ratio Change
17/05/2024
Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage [...]
DBV Technologies annonce son intention de modifier le ratio d'ADS
17/05/2024
Châtillon, France, le 17 mai 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), une société [...]
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
17/05/2024
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to [...]
T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
17/05/2024
LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its [...]
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
17/05/2024
FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product [...]
Viracta Therapeutics Announces New Employment Inducement Grants
17/05/2024
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients [...]
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
17/05/2024
TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, proudly welcomes [...]
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
17/05/2024
-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of [...]
Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology
17/05/2024
Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita In vitro and in vivo data of KM-001 and KM-023 [...]
Assure & Danam Reschedule Corporate Update Call & Webcast
17/05/2024
DENVER, May 17, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that [...]
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
17/05/2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. TARRYTOWN, N.Y. and [...]
Better Choice Company Announces First Quarter 2024 Results
17/05/2024
EPS Growth of 28% Year Over Year to $(3.60) Adjusted EBITDA 1 Growth of 27% Year Over Year to $(1.4) Million Adjusted EBITDA Margin 1 of (18)% , a 299 Basis Point Expansion Year Over Year TAMPA, Fla., May 17, 2024 ( [...]
Hepatitis: The silent killer
17/05/2024
Safe vaccination, testing and treatment options widely available JEFFERSON CITY, Mo., May 17, 2024 (GLOBE NEWSWIRE) -- May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care [...]
Le King Faisal Specialist Hospital & Research Centre lauréat du prix « Tech Impact » VBHC 2024
17/05/2024
RIYAD, Arabie Saoudite, 17 mai 2024 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre, ci-après « KFSH&RC », soit l’hôpital spécialisé et centre de recherche King Faisal, a franchi un cap [...]
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
17/05/2024
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its [...]

Pages